Novel use of riociguat in infants with severe pulmonary arterial hypertension unable to wean from inhaled nitric oxide

Novel use of riociguat in infants with severe pulmonary arterial hypertension unable to wean from inhaled nitric oxide

IntroductionRiociguat, an oral soluble guanylate cyclase stimulator, has been approved for use in adults with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension. However, there is limited data on its therapeutic use in children.Case PresentationWe report the case...

Full description

Bibliographic Details
Main Authors:	L. T. Domingo, D. D. Ivy, S. H. Abman, A. M. Grenolds, J. T. MacLean, J. A. Breaux, K. J. Minford, B. S. Frank
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-12-01
Series:	Frontiers in Pediatrics
Subjects:	riociguat pediatric pulmonary arterial hypertension pulmonary vasodilator targeted therapy pulmonary vasoreactivity TBX4 mutation
Online Access:	https://www.frontiersin.org/articles/10.3389/fped.2022.1014922/full

Similar Items

CLINICAL CASE OF REPLACEMENT OF ENDOTHELIN RECEPTOR ANTAGONIST (BOSENTAN) BY SOLUBLE GUANYLATE CYCLASE STIMULATOR (RIOCIGUAT) IN THE PATIENT WITH PULMONARY ARTERIAL HYPERTENSION
by: E. A. Devetyarova, et al.
Published: (2018-06-01)

Riociguat in children with pulmonary arterial hypertension: The PATENT–CHILD study
by: Humberto García Aguilar, et al.
Published: (2022-07-01)

Better efficacy of sequential combination with balloon pulmonary angioplasty after long‐term riociguat for patients with inoperable chronic thromboembolic pulmonary hypertension
by: Wei Wang, et al.
Published: (2024-07-01)

Switching from sildenafil to riociguat for the treatment of PAH and inoperable CTEPH: Real-life experiences
by: Asger Andersen, et al.
Published: (2017-01-01)

Riociguat: an upcoming therapy in chronic thromboembolic pulmonary hypertension?
by: N. H. Kim
Published: (2010-03-01)

Evaluating Riociguat in the Treatment of Pulmonary Arterial Hypertension: A Real-World Perspective
by: Mihalek AD, et al.
Published: (2022-10-01)

Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study
by: Vallerie V. McLaughlin, et al.
Published: (2017-12-01)

Results of long-term riociguat therapy, including a switching strategy from sildenafil, in patients with pulmonary hypertension of various genesis
by: S. A. Musashaykhova, et al.
Published: (2023-11-01)

Meta‐Analysis of Real‐World Clinical Practice to Assess the Effectiveness of Riociguat in Treating Chronic Thromboembolic Pulmonary Hypertension
by: Esra Pamukçu, et al.
Published: (2025-02-01)

Riociguat is a novel medication for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
by: N. A. Tsareva, et al.
Published: (2016-12-01)

Frequency of acute vasodilator response (AVR) in incident and prevalent patients with pulmonary arterial hypertension: Results from the pulmonary vascular disease phenomics study
by: Mario Naranjo, et al.
Published: (2023-07-01)

The effects of oxygenation on acute vasodilator challenge in pulmonary arterial hypertension
by: Matthew D. Rockstrom, et al.
Published: (2024-04-01)

THE ROLE OF RIOCIGUAT IN THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH CONNECTIVE TISSUE DISEASE
by: O. Ya. Vasiltseva, et al.
Published: (2019-12-01)

Analysis of riociguat and desmethyl riociguat by UPLC-MS/MS and its interaction with quercetin
by: Qingqing Li, et al.
Published: (2024-09-01)

Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis
by: Yu-Yang Liu, et al.
Published: (2023-01-01)

Corrigendum: Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis
by: Yu-Yang Liu, et al.
Published: (2023-02-01)

Type 1 neurofibromatosis complicated by pulmonary arterial hypertension: a case report
by: Murathan Küçük, et al.
Published: (2017-07-01)

Acute vasoreactivity testing during right heart catheterization in chronic thromboembolic pulmonary hypertension: Results from the pulmonary vascular disease phenomics study
by: Robert P. Frantz, et al.
Published: (2023-01-01)

Riociguat inhibits ultra‐large VWF string formation on pulmonary artery endothelial cells from chronic thromboembolic pulmonary hypertension patients
by: Takayuki Jujo Sanada, et al.
Published: (2022-10-01)

Evaluation of patients with severe pulmonary hypertension and a range of comorbidities prescribed inhaled treprostinil
by: Aparna C. Swaminathan, et al.
Published: (2024-11-01)

Vasoreactive testing prevalence and characteristics in patients with idiopathic pulmonary arterial hypertension
by: Goncharova Natalia, et al.
Published: (2025-01-01)

Advances in Balloon Pulmonary Angioplasty for the Treatment of Chronic Thromboembolic Pulmonary Hypertension
by: GAO Luyang, et al.
Published: (2023-09-01)

Soluble Guanylate Cyclase Stimulators for Chronic Thromboembolic Pulmonary Hypertension Patients Treatment: New Data
by: M. A. Simakova, et al.
Published: (2020-05-01)

Vasoreactivity testing in pulmonary hypertension associated with congenital heart disease
by: A. A. Shmalts, et al.
Published: (2022-10-01)

Possibilities of long-term effective treatment of idiopathic pulmonary arterial hypertension by replacing sildenafil with riociguat and using sequential combination therapy: case report
by: S. A. Musashaykhova, et al.
Published: (2022-12-01)

Inhaled nitric oxide: are expectations justified?
by: I. A. Kozlov
Published: (2024-12-01)

Treatment Strategy Options in Inoperable Chronic Thromboembolic Pulmonary Hypertension Patients
by: N. V. Marukyan, et al.
Published: (2021-05-01)

Persistent pulmonary hypertension of the newborn: Recent advances in pathophysiology and treatment
by: Joaquim E.B. Cabral, et al.
Published: (2013-05-01)

Comparison of intravenous sildenafil with inhaled nitric oxide for acute vasodilator testing in pulmonary arterial hypertension
by: Shine Kumar, et al.
Published: (2022-10-01)

Modern possibilities of echocardiographic diagnosis in pulmonary arterial hypertension
by: A. A. Klimenko, et al.
Published: (2025-01-01)

Clinical case of a patient with pulmonary capillary hemangiomatosis: rapid progression or lost time?
by: E. A. Devetyarova, et al.
Published: (2021-11-01)

Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Chronic thromboembolic pulmonary hypertension
by: Eckhard Mayer, et al.
Published: (2014-01-01)

Sildenafil Use in the Treatment of Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension: A Case Series
by: Amna Qasim, et al.
Published: (2018-10-01)

Self-reported physician practices in pulmonary arterial hypertension: Diagnosis, assessment, and referral
by: Susan Polanco-Briceno, et al.
Published: (2016-04-01)

Predictors of hospitalization for respiratory failure among patients with sarcoidosis‐associated pulmonary hypertension
by: Shameek Gayen, et al.
Published: (2023-04-01)

Revisiting a Distinct Entity in Pulmonary Vascular Disease: Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
by: Munish Sharma, et al.
Published: (2021-04-01)

Inhaled nitric oxide testing in predicting prognosis in pulmonary hypertension due to left‐sided heart diseases
by: Taijyu Satoh, et al.
Published: (2023-12-01)

Persistent Pulmonary Hypertension of the Newborn: Pathophysiological Mechanisms and Novel Therapeutic Approaches
by: Sofia Martinho, et al.
Published: (2020-07-01)

Chronic thromboembolic pulmonary hypertension after an acute pulmonary embolism: fundamental concepts of diagnosis and review of current treatment options
by: N. A. Cherepanova, et al.
Published: (2021-10-01)

Rapidly Progressive Idiopathic Pulmonary Arterial Hypertension in a Paediatric Patient Treated with Lung Transplantation
by: Filip Baszkowski, et al.
Published: (2023-10-01)